Capstone Investment Advisors
ALXN

Capstone Investment Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Capstone Investment Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-868,549
Closed -$160M – 2120
2021
Q2 		$160M Sell
868,549
-308,950
-26% -$53M 0.36% 51
2021
Q1 		$180M Buy
1,177,499
+979,455
+495% +$152M 0.53% 32
2020
Q4 		$30.9M Buy
+198,044
New +$25.4M 0.1% 162
2020
Q1 		– Sell
-18,634
Closed -$1.83M – 1424
2019
Q4 		$2.02M Sell
18,634
-9,287
-33% -$993K 0.01% 828
2019
Q3 		$2.73M Buy
27,921
+22,173
+386% +$2.5M 0.02% 632
2019
Q2 		$753K Buy
5,748
+4,737
+469% +$611K 0.01% 1020
2019
Q1 		$137K Sell
1,011
-8,712
-90% -$1.08M ﹤0.01% 1178
2018
Q4 		$947K Buy
9,723
+5,651
+139% +$668K 0.01% 629
2018
Q3 		$566K Buy
+4,072
New +$511K 0.01% 759
2017
Q2 		– Sell
-21,619
Closed -$2.62M – 1019
2017
Q1 		$2.62M Buy
+21,619
New +$2.79M 0.07% 231
2016
Q3 		– Sell
-8,400
Closed -$980K – 957
2016
Q2 		$980K Sell
8,400
-17,375
-67% -$2.47M 0.02% 355
2016
Q1 		$3.59M Buy
+25,775
New +$3.78M 0.11% 126

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Capstone Investment Advisors's ALXN Position: Q3 2021 in Review

Capstone Investment Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 868,549 shares — an estimated $160M sold.

Capstone Investment Advisors first reported a position in ALXN in Q1 2016 and held it in 12 quarters. The position peaked at $180M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Capstone Investment Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 868,549 Alexion Pharmaceuticals shares in Q3 2021, an estimated $160M.
  • Capstone Investment Advisors first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 12 quarters.
  • Capstone Investment Advisors's Alexion Pharmaceuticals position peaked at $180M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Capstone Investment Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.